Novartis’ President of Oncology announces retirement
December 15, 2017Medical Communications Bruno Strigini, Novartis, pharma
Novartis has announced that the President of its oncology business, Bruno Strigini, is to retire next year, citing personal reasons …
BMS partners again with the company behind Opdivo
December 14, 2017Medical Communications, Sales and Marketing Bristol-Myers Squibb, biotech, drugs, opdivo, pharma, pharmaceutical
Bristol-Myers Squibb has once again struck a deal with Ono Pharmaceutical for multiple programs, seeking to discover a boost to …
Novartis, Abbott targeted by Indian watchdog over allegations of price collusion
December 14, 2017Sales and Marketing Abbott, Emcure Pharma, Galdus, Novartis, USV, diabetes, pharma, vildagliptin
Novartis, Abbott, Emcure Pharma and USV have become the targets of an investigation by the Competition Commission of India (CCI) …
Working Life: Dr Rav Seeruthun, Medical Director of Roche UK
December 14, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Roche, biotech, drugs, pharma, pharmaceutical
Pharmafile.com sat down with Dr Rav Seeruthun, Medical Director of Roche UK, to discuss his career thus far and the lessons …
FDA launches new method for antibiotic prescription
December 14, 2017Medical Communications antibiotic resistance, biotech, drugs, pharma, pharmaceutical
The fight against the growth of antibiotic resistance has become a major talking point internationally in recent years and the …
‘Mind-blowing’ gene therapy could herald a cure for haemophilia, study shows
December 14, 2017Research and Development haemophilia, pharma
A team of clinical researchers at Barts Health NHS Trust and Queen Mary University of London have reported that a …
What will Pfizer do with its second Remicade biosimilar?
December 14, 2017Sales and Marketing Ixifi, Johnson & Johnson, Pfizer, Remicade, biosimilars, biotech, drugs, inflectra, pharma, pharmaceutical
Pfizer is now in the unusual position of owning two biosimilars to Johnson & Johnson’s Remicade, though one of these …
Daiichi Sankyo: Two steps forward, one step back in cancer deals
December 14, 2017Sales and Marketing Daiichi Sankyo, biotech, drugs, pharma, pharmaceutical
Daiichi Sankyo had a busy day in terms of its deals in oncology, not only did it tear up its …
Mundipharma names new President and CEO
December 13, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Mundipharma, Napp, Napp Pharmaceuticals, appointment
Shortly following its announcement of Philippe Mazas as Chief Information Officer, Mundipharma has revealed it has appointed Alberto Martinez as …
Sanofi sees pipeline fruition in 2018
December 13, 2017Research and Development Sanofi, biotech, drugs, pharma, pharmaceutical
In news that Sanofi will no doubt be hoping should divert attention away from the Dengvaxia scandal, the company revealed …
Blood cancer patients over 75 are significantly underrepresented in clinical trials, study finds
December 13, 2017Research and Development FDA, blood cancer, leukaemia, lymphoma, myeloid leukaemia, pharma
The FDA’s first comprehensive analysis of clinical trial enrolment in older patients with blood cancers has revealed that the population …
FDA cracks down on snortable chocolate powder
December 13, 2017Medical Communications, Research and Development FDA, biotech, drugs, pharma, pharmaceutical
The FDA has taken action on Coco Loko and Legal Lean Syrup, both made by Arco Globus Trading LLC, after …
J&J’s Darzalex cuts risk of disease progression and death by 50%, new study shows
December 13, 2017Research and Development Genmab, J&J, JJ, Janssen, Johnson & Johnson, darzalex, multiple myeloma, pharma
Johnson and Johnson has revealed data which demonstrates that Darzalex (daratumumab), when combined with a regimen of bortezomib, melphalan and …
Tumultuous times at Teva continue, with Chairman exit
December 13, 2017Medical Communications, Research and Development Teva, biotech, drugs, pharma, pharmaceutical
In the latest addition to a number of high profile exits from Teva, previous interim Chief Executive and the company’s …
FDA approves first short-acting, follow-on biologic of Lilly’s Humalog insulin product
December 12, 2017Manufacturing and Production, Sales and Marketing Admelog, FDA, Humalog, Sanofi, diabetes, insulin, pharma
The FDA has announced its approval of Sanofi’s Admelog (insulin lispro), the first follow-on biologic version of Eli Lilly’s Humalog …
Latest US company accused of price gouging, after 2,469% increase
December 12, 2017Manufacturing and Production, Sales and Marketing Avondale Pharmaceutical, Niacor, biotech, drugs, pharma, pharmaceutical
It seems that no matter how much bad press comes their way, certain pharmaceutical companies are more than happy to …
Single, high-dose vaccine could provide better protection against cholera outbreaks, new research shows
December 12, 2017Manufacturing and Production, Research and Development Africa, Asia, Caribbean, Cholera, Vaccine, paxvax, pharma
A team of researchers at the University of Maryland School of Medicine (UMSOM) has been assessing the effectiveness of a …
Sanofi issues US-wide recall for arthritis product, after adverse events
December 12, 2017Manufacturing and Production Sanofi, Synvisc-One, biotech, drugs, pharma, pharmaceutical
Sanofi has announced a recall of 12,380 syringes of its Synvisc-One product for the treatment of osteoarthritis, after it was …
Ionis scores huge breakthrough in Huntington’s, Roche licenses drug
December 12, 2017Manufacturing and Production, Research and Development Ionis, Roche, biotech, drugs, pharma, pharmaceutical
Ionis Pharmaceuticals has revealed findings from its Phase 1/2a study into a treatment for Huntington’s disease and the strong data …
Exscientia appoints Oxford Innovation Sciences founder and ex-Lansdowne CEO as Deputy Chairman
December 11, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alex Snow, Exscientia, appointment
Exscientia, an Oxford-based drug design firm which has made headlines this year for its collaboration with GlaxoSmithKline to leverage its …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
